Moreover, the combination of atezolizumab (anti-PD-1) and bevacizumab (anti-VEGF) in patients with unresectable HCC (including but not stratifying viral and non-viral etiologies) showed a progression-free survival rate of over 15 months that is superior compared to multikinase inhibitor sorafenib [34] and is thus now considered first line therapy for HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.